Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 1
2020 5
2021 9
2022 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Antioxidants with two faces toward cancer.
Dastmalchi N, Baradaran B, Latifi-Navid S, Safaralizadeh R, Khojasteh SMB, Amini M, Roshani E, Lotfinejad P. Dastmalchi N, et al. Among authors: lotfinejad p. Life Sci. 2020 Oct 1;258:118186. doi: 10.1016/j.lfs.2020.118186. Epub 2020 Aug 6. Life Sci. 2020. PMID: 32768586 Review.
PD-1/PD-L1 axis importance and tumor microenvironment immune cells.
Lotfinejad P, Kazemi T, Mokhtarzadeh A, Shanehbandi D, Jadidi Niaragh F, Safaei S, Asadi M, Baradaran B. Lotfinejad P, et al. Life Sci. 2020 Oct 15;259:118297. doi: 10.1016/j.lfs.2020.118297. Epub 2020 Aug 19. Life Sci. 2020. PMID: 32822718 Review.
Tumor-derived exosomal PD-L1 in progression of cancer and immunotherapy.
Rasihashemi SZ, Rezazadeh Gavgani E, Majidazar R, Seraji P, Oladghaffari M, Kazemi T, Lotfinejad P. Rasihashemi SZ, et al. Among authors: lotfinejad p. J Cell Physiol. 2022 Mar;237(3):1648-1660. doi: 10.1002/jcp.30645. Epub 2021 Nov 25. J Cell Physiol. 2022. PMID: 34825383 Review.
The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers.
Kooshkaki O, Derakhshani A, Safarpour H, Najafi S, Vahedi P, Brunetti O, Torabi M, Lotfinejad P, Paradiso AV, Racanelli V, Silvestris N, Baradaran B. Kooshkaki O, et al. Among authors: lotfinejad p. Int J Mol Sci. 2020 Jul 16;21(14):5034. doi: 10.3390/ijms21145034. Int J Mol Sci. 2020. PMID: 32708748 Free PMC article. Review.
COVID-19 Infection: Concise Review Based on the Immunological Perspective.
Lotfinejad P, Asadzadeh Z, Najjary S, Somi MH, Hajiasgharzadeh K, Mokhtarzadeh A, Derakhshani A, Roshani E, Baradaran B. Lotfinejad P, et al. Immunol Invest. 2022 Feb;51(2):246-265. doi: 10.1080/08820139.2020.1825480. Epub 2020 Sep 28. Immunol Invest. 2022. PMID: 32981399 Review.
Prognostic Role and Clinical Significance of Tumor-Infiltrating Lymphocyte (TIL) and Programmed Death Ligand 1 (PD-L1) Expression in Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis Study.
Lotfinejad P, Asghari Jafarabadi M, Abdoli Shadbad M, Kazemi T, Pashazadeh F, Sandoghchian Shotorbani S, Jadidi Niaragh F, Baghbanzadeh A, Vahed N, Silvestris N, Baradaran B. Lotfinejad P, et al. Diagnostics (Basel). 2020 Sep 17;10(9):704. doi: 10.3390/diagnostics10090704. Diagnostics (Basel). 2020. PMID: 32957579 Free PMC article. Review.
17 results